Company Profile
Lenus Pharma Lenus Pharma GmbH (Ltd) is a fully privately owned and funded company, incorporated under Austrian law and having its headquarters located at SeebÜckgasse 59, A-1160 Vienna/Austria. Lenus Pharma specialises in the research, development, marketing and distribution of nutraceuticals, according to European Union (EU) classification named „foods for special medical purposes� (EU Commission Directive 1999/21/EC). The philosophy of the company is to develop
innovative products, meeting unmet medical needs, based on Evidence-based Medicine. Beside product development and international market expansion, Lenus Pharma is engaged in the local distribution and marketing of its own product range covering the urological, gynecological and ophthalmological field in Austria and Slovakia.
Starting as the pioneer in the segment of Food for Special Medical Purpose especially for childwish, Lenus Pharma has developed to an international successful Pharma company.
The art of holistic approach
The human and their desires, the human and their worries: Lenus Pharma has made to it´s aim to satisfy human expectations. We do not look singularly at the medical components, but analyse the problem in its totality by looking at the whole person, including understanding its physical, nutritional, environmental, emotional, social, spiritual and lifestyle values.
All these components are driving and influencing the development of our products. Our dedication to this holistic approach - together with our implicit wish of making people’s lives healthier is the cornerstone of our success.
Nam reperum de est, ex enessum ut veres pro volut perum as enist unditaturit remquassum delenda esendam re laborpor aliquas cus es rem illaboratiam reperibus aut resciunt. Rum fugitem olorem de perite dio. Et etur, comnis audit, et odis et et aut autet iur sit lam dignis aperiatur, odis ea voluptati sundandamus atquiandem as maio molecusantio
1 is good enough.
Only
the best
We, at Lenus Pharma, focus on quality. We are benchmarking ourselves not only according to our own high standards, but also to external, international guidelines for pharmaceuticals. Evidence Based Medicine EBM: All products of Lenus Pharma are based on scientific and clinical studies, published in renowned journals. Good Manufacturing Practice GMP: All our products are produced in accordance with GMP, the highest quality standard for the production of pharmaceuticals. So from the selection of raw materials to the final product, we ensure the highest quality requirements.
P M G
ING
CTUR NUFA
D MA GOO TICE PRAC
Product
Portfolio
– it’s the combination and concentration of nutrients that count
PROfertil® for the dietary management of sub-fertility in men. With PROfertil®, Lenus Pharma has successfully developed a nutraceutical (Food for Special Medical Purposes) for the treatment of male sub-fertility - supporting couples to overcome their long-lasting unfulfilled desire for children. With this specific nutraceutical combination the problems of sub-fertile men (quality, quantity and motility of sperm cells) are treated by its roots and can be improved in many cases.
The specific and study proven composition of PROfertil® is adjusted to the special nutritional needs in the indicated area of application and meets particularly the increased nutrient requirements of men with diet-related sub-fertility.
Product
Portfolio
PROfamily – from the wish for a child to the child of your wish! PROfamily product line - for the dietary management of women from the wish for a child to lactation.
PROfertil® female - optimal preparation of the female body towards pregnancy. Fulfills the particular nutritional requirements of women with child-wish until the end of the third month of pregnancy.
PROpregna®- the ideal compensation in an intensive period of life. Fulfills the particular nutritional requirements of women during pregnancy.
PROglanat® - nutritional supply during lactation period at the best.
PROSTAvital
PROSTAvital® for t of men with prostate malignant diso
Prostate problems are accompanying symptom About one third of men prostate problems and become one of the mo
l® - Victory for life!
the dietary management e cancer or other benign or orders of the prostate.
e among the most common ms of the aging process in men. n over 50 years struggle with d prostate cancer has already ost prevalent cancer in men.
– it’s the combination and concentration of nutrients that count
®
®
®
PROmacula® – and brightness remains!
PROmacula® product line - PROmacula® areds, PROmacula® max!, PROmacula® lutein and PROmacula® omega for the dietary management of Age-related macular degeneration (AMD). With the PROmacula® line of products, Lenus Pharma has successfully managed to develop a Food for Special Medical Purpose (FSMP) for persons with advanced age-related macular degeneration. It was the first product in Austria and is the only complete product line for the indication of AMD, which is in line with the A.R.E.D.S. study and thus preserves the eyesight. PROmacula® lutein fully complies with the A.R.E.D.S 2 study.
History of
PROfertil®
Based on the increasing awareness of male fertility problems, a fruitful cooperation with doctors and researchers of the Vienna University Hospital has started in 2002 with the goal to develop an innovative product which improves male fertility. Following a period of compound-analysis, efficacyscreening and developmentstudies in the search for the
ideal combination of nutrients, the pilot study was finally designed in 2005. In course of the product development, the Vienna University Hospital also conducted this pilot study which convincingly showed significant positive results already for the first interimanalysis!
In 2006, PROfertil® had become ready for patent application and serialproduction and was notified in Austria as the first EU country, according to EU Directive 1999/21/EU on Foods for Special Medical Purposes.
PROfertil® Patents
PROfertil® is a patented product with worldwide patent granted.
Austrian Patent –
503 219
2008
Eurasian Patent –
015422
2011
European Patent –
1 978 949
2012
US Patent –
13/575,027
pending
PROfertil® is a registered trademark in Austria, European Union, the US, the Middle East and Asia.
Studies and representation of
PROfertil®
The goal of Lenus Pharma is continuously providing studies of our products based on the latest scientifical standard. From the first pilot study of PROfertil® onwards, the medical team of Lenus Pharma is steadily working on new studies in cooperation with specialists.
Study
Number of patients
Published/presented
120
EAU Bratislava 2010
51
Fortbildungstagung der österr. Gesellschaft für Urologie und Andrologie mit Jahreshauptversammlung der ÖGU Linz 2010; EAU Bratislava 2010
3. Controlled study 2010: „Improvement of sperm quality after micronutrient supplementation
205 ( 132 therapy group, 73 control group)
e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism Vol. 7 Issue 1 (December 2011) & European Urological Review Volume 6 Issue 2
4. DNA-study 2010-2011: “Sperm DNA fragmentation decreases after micronutrient supplementation”
107 (67 therapy group, 40 control group)
Menopause/ Andropause and Anti-Aging Congress Vienna (December 2011) Poster presentation
1. Pilot study 2006-2008: „Micronutrients change the influence of sperm quality in fertility”
2. Varicocele study 2009: “Micronutrients as an alternative to fertility treatment in men with subclinical varicocele”
In 2010 the positive results of the pilot study (2006 -2008, with 120 patients) and also the data of a new varicocele study (2009, with 55 patients) were presented at the 10th Central European Meeting (CEM) of the European Association of Urology in Bratislava/Slovakia. In December 2011 the controlled study of PROfertil® - Improvement of sperm quality after micronutrient supplementation –was published in the e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, Vol. 7 Issue 1. During the Menopause/Andropause and Anti-Aging Congress in Vienna (December 2011) the first significant results of the latest study on PROfertil® were presented at the poster-session under the title – Sperm DNA Fragmentation Index Decreases After Micronutrient Supplementation. Own studies and continuous research have been the backbone of the success of PROfertil®. Therefore further studies on PROfertil® are planned for the near future in order to increase PROfertil®’s position as the most evidence-based male fertility product on the international markets.
Outlook and future prospects: Study in process: Double blind, controlled multi-center study – PROfertil vs. one of the most investigated single substance (with partly survey of DNA).
PROfertil® International
PROfertil® available in: Early in 2007, Lenus Pharma started its international expansion with PROfertil® and gained increasing popularity. Since our strategy is to have a constant and steady expansion with well selected Distribution partners, the company has gone through a successful and continuous growth on the international market.
(May 2013) 2006
Austria
2013
Hungary
2006
Slovakia
2013
Poland
2007
Azerbaijan
2013
Rep. of Korea
2008
Latvia
2013
Taiwan
2008
Estonia
2013
Saudi Arabia
2008
Lithuania
2013
Bulgaria
2008
Czech Republic
2013
Iraq
2008
Kosovo
2013
Jordan
2009
Germany
2013
UAE
2009
Ukraine
2009
Albania
2010
Russia
2010
Serbia
2011
Italy
2011
Georgia
2012
Romania
2012
Turkey
2012
Spain
• EAU - Congresses of the European Association of Urology
2012
Libya
2012
Netherlands
2012
Tunisia
• ESHRE - Congresses of the European Society of Human Reproduction and Embryology
2012
Kuwait
2012
Bosnia& Herzegovina
2012
Macedonia
2012
Montenegro
2012
Greece
Lenus Pharma is regularly represented at the following international medical congresses:
• AUA - Congresses of the American Urological Association • MEFS - Congresses of the Middle East Fertility Society • Arab Health • ASA - Congresses of the American Society of Andrology • COGI - World Congresses on Controversies in Obstetrics, Gynecology and Infertility Besides international congresses, Lenus Pharma is participating at major medical congresses in the fields of Urology, Gynecology and Human Reproduction in its home markets Austria and Slovakia. Status as of May 2013
Social
Responsibility Social engagement is an important matter of concern to us, therefore Lenus Pharma supports several social and charity organizations, which have the aim to support life and health:
Sponsor of the Life Ball – “Clinton Health Access Initiative (CHAI) ” of the William J. Clinton Foundation
Special Olympics
Fertility Europe - European umbrella association of 31 European country organizations and associations dedicated to fertility issues.
Austrian Cancer Aid
Austrian fundraising campaign “Licht ins Dunkel”
Support for the University Teaching Hospital, Lusaka/Zambia
Local events
Lenus Pharma/Managing Partner
Rewards 09/2006:
Woman Award Austria for outstanding success in Innovation
06/2007:
Austrian most innovative company
09/2007:
Great Women of the 21st Century Award (US)
Contact For more information about Lenus Pharma and our products, please contact: Lenus Pharma GmbH, Seebรถckgasse 59, A-1160 Vienna/Austria, t: +43 (1) 405 14 19 f: +43 (1) 405 14 19 - 20 m: office@lenuspharma.com w: www.lenuspharma.com Company Register No. FN 282292k at the Commercial Court, Vienna.
Company Profile, May 2013